Phreesia, Inc. (PHR)
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
- Symbol
- PHR
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Health Information Services
- Market cap
- $624.97M
- 52 week range
- 7.77 - 25
Valuation
- Share price
- $9.68 (close of 2026-09-23)
- P/E (TTM)
- 56.11x
- Price to book
- 1.68x
- Price to free cash flow
- 7.74x
- Enterprise value
- $618.28M
- Book value per share
- $6.01
Price performance
| Period | Change |
|---|
| 1 day | -3.49% |
| 5 days | -6.47% |
| 1 month | -20.13% |
| 3 months | +5.79% |
| 6 months | -17.97% |
| Year to date | -42.79% |
| 1 year | -59.33% |
| 3 years | -45.50% |
| 5 years | -85.15% |
| All time | -61.40% |
Profitability and growth
- Return on equity
- 0.68%
- Return on invested capital
- -0.90%
- Return on assets
- 0.35%
- Return on capital employed
- -1.38%
- Gross margin
- 63.06%
- Net margin
- 0.49%
- EBITDA margin
- 5.31%
- Revenue growth
- 13.97%
- Net income growth
- 103.94%
- Free cash flow growth
- 186.05%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 12.92%
- Current ratio
- 1.76x
- Net debt to EBITDA
- -0.13x
Latest reported year
- Period end
- 2026-01-31
- Fiscal year
- 2026
- Revenue
- $467.82M
- Cost of revenue
- $172.80M
- Gross profit
- $295.01M
- EBITDA
- $24.84M
- Net income
- $2.31M
- Earnings per share
- $0.04
- Research and development
- $121.48M
- Shares outstanding
- 59.74M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2026-01-31 | $467.82M | $295.01M | $2.31M | $0.04 |
| 2025-01-31 | $410.48M | $256.99M | $-58.53M | $-1.02 |
| 2024-01-31 | $345.99M | $202.80M | $-136.88M | $-2.51 |
| 2023-01-31 | $280.91M | $146.34M | $-176.15M | $-3.36 |
| 2022-01-31 | $213.23M | $110.54M | $-118.16M | $-2.37 |
| 2021-01-31 | $148.68M | $80.38M | $-27.29M | $-0.69 |
| 2020-01-31 | $124.78M | $66.14M | $-20.29M | $-4.50 |
| 2019-01-31 | $99.89M | $51.30M | $-15.06M | $-24.53 |
| 2018-01-31 | $79.83M | $40.42M | $-18.19M | $-24.81 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2026-01-31 | 63.06% | 0.49% | 0.68% | -0.90% |
| 2025-01-31 | 62.61% | -14.26% | -22.10% | -29.28% |
| 2024-01-31 | 58.61% | -39.56% | -54.44% | -77.58% |
| 2023-01-31 | 52.09% | -62.71% | -61.20% | -146.74% |
| 2022-01-31 | 51.84% | -55.41% | -28.32% | -97.94% |
| 2021-01-31 | 54.07% | -18.36% | -10.37% | -43.62% |
| 2020-01-31 | 53.00% | -16.26% | -19.92% | -39.06% |
| 2019-01-31 | 51.36% | -15.08% | 7.14% | - |
| 2018-01-31 | 50.63% | -22.79% | 10.85% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2026-01-31 | $73.83M | $2.66M |
| 2025-01-31 | $84.22M | $1.94M |
| 2024-01-31 | $87.52M | $3.15M |
| 2023-01-31 | $176.68M | $246.00K |
| 2022-01-31 | $313.81M | $360.00K |
| 2021-01-31 | $218.78M | $1.63M |
| 2020-01-31 | $90.31M | $19.44M |
| 2019-01-31 | $1.54M | $27.92M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2026-01-31 | $67.71M | $67.45M |
| 2025-01-31 | $23.67M | $66.97M |
| 2024-01-31 | $-38.18M | $71.61M |
| 2023-01-31 | $-94.86M | $58.77M |
| 2022-01-31 | $-93.13M | $36.14M |
| 2021-01-31 | $-8.35M | $13.49M |
| 2020-01-31 | $-6.19M | $6.18M |
| 2019-01-31 | $-6.85M | $1.45M |
| 2018-01-31 | $-17.73M | $805.00K |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-09-02 | Jul/2026 | $0.10 |
| 2026-05-27 | - | - |
| 2026-03-30 | - | - |
| 2025-12-08 | - | - |
| 2025-09-04 | - | - |
| 2025-05-28 | - | - |
| 2025-03-12 | - | - |
| 2024-12-09 | - | - |
Filings and sources
- Company website
- phreesia.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades